

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP05/000191

International filing date: 07 January 2005 (07.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: EP  
Number: 04075001.0  
Filing date: 07 January 2004 (07.01.2004)

Date of receipt at the International Bureau: 11 February 2005 (11.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

- 7. 01. 2005

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-  
gen stimmen mit der  
ursprünglich eingereichten  
Fassung der auf dem näch-  
sten Blatt bezeichneten  
europäischen Patentanmel-  
dung überein.

The attached documents  
are exact copies of the  
European patent application  
described on the following  
page, as originally filed.

Les documents fixés à  
cette attestation sont  
conformes à la version  
initialement déposée de  
la demande de brevet  
européen spécifiée à la  
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

04075001.0

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

R C van Dijk



PCT/EP200 5 / 0 0 0 1 9 . 1

Anmeldung Nr:  
Application no.: 04075001.0  
Demande no:

Anmeldetag:  
Date of filing: 07.01.04  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Taal, Leendert  
Loakendiek 2  
7255 NL Hengelo (Gld)  
PAYS-BAS  
Taal-Vlas, Anita Monique  
Loakendiek 2  
7255 NL Hengelo (Gld)  
PAYS-BAS

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se référer à la description.)

Kit for use in the treatment of lupus and tale and mane eczema

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

A61K35/78

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL  
PT RO SE SI SK TR LI

**KIT FOR USE IN THE TREATMENT OF LUPUS AND TALE AND MANE  
ECZEMA**

The present invention relates to a kit comprising six botanic  
5 compositions. The invention further relates to a kit for use  
in the treatment of disorders in mammals, like humans,  
horses, cows, pigs and pets, to its use in the treatment of  
lupus, multiple sclerosis or rheumatoid arthritis in humans  
or tale and mane eczema in horses and to the use of the kit  
10 as a medicament.

Lupus and tale and mane eczema are diseases which are  
characterized by a complete derangement of the metabolism in  
a human or horse, respectively. This results in an  
15 accumulation of homotoxins in the connective tissues located  
in the skin of humans or in the tale region or mane region of  
horses. However, it may also manifest itself in other parts  
of the body, such as internal organs.

The skin of human patients suffering from lupus is often very  
20 sensitive to light. In severe cases direct light exposure  
should be avoided, ultimately leading to a social isolation  
of the patient. Further, it is known that patients suffering  
from lupus may have a poorly working liver or kidney due to  
progressive attacks of inflammation.

25 Horses suffering from tale and mane eczema feel a constant  
itching in the affected places. To alleviate this itching,  
horses scratch their affected places on rough surfaces.  
However, this scratching leads to severe inflammation of the  
affected places and ultimately the horses are no longer  
30 capable of functioning normally.

Although, lupus and tale and mane eczema are diseases which  
are known for many years, a truly effective cure has not yet

been found. Treatments used at present focus on symptoms, i.e. inflammation, but do not treat the disease itself.

The objective of the present invention is to provide for a  
5 medicament which is truly effective for use in the treatment of lupus and tale and mane eczema.

A first aspect of the present invention relates to a kit comprising:

- 10 - a first composition comprising leaves of *Melissa Officinalis*, or parts thereof;
- a second composition comprising *Eleutherococcus senticosus*, or parts thereof;
- a third composition comprising *Avena sativa*, or  
15 parts thereof;
- a fourth composition comprising *Ballota Nigra*, or parts thereof;
- a fifth composition comprising roots of *Glycyrrhiza glabra/gan cao*, or parts thereof; and
- 20 - a sixth composition comprising roots of *Unicaria Tomentosa*, or parts thereof.

It is believed that one of the pharmaceutically active compounds in the leaves of *Melissa Officinalis* is rose mary acid. It is further believed that the pharmaceutically active  
25 compounds of *Eleutherococcus senticosus* are present in the polyphenol-fraction. Moreover, one of the pharmaceutically active compounds in parts of *Bollota Nigra* is most likely caffeic acid. Further, it is believed that the pharmaceutically active compounds of the roots of *Glycyrrhiza*  
30 *glabra/gan cao* are present in the saponin-fraction and that the pharmaceutically active compounds of the roots *Unicaria Tomentosa* are present in the alkaloid-fraction.

The above mentioned kit of compositions is especially suited for human patients suffering from lupus and horses suffering from tale and mane eczema, although other mammals may also be treated with it. By administering the compositions of the kit to patients, the system-reticulo-endothelial blockade is lifted and the biofeedback restored. This leads to an improvement of the overall physical condition of the patient. It is believed that due to the improvement of the physical condition of the patient, the homotoxins which are present in connective tissue of the body are broken down. This stops the accumulation of homotoxins in the connective tissue, resulting in a halt to the inflammation of the skin and other organs. Due to the overall improvement of the physical condition of patients, the above mentioned kit can also be beneficial for human patients suffering from other diseases than lupus, such as for example multiple sclerosis or rheumatoid arthritis.

In a preferred embodiment of the kit,

- 20                   - the first composition comprises a unit dose of 100-1000 mg of leaves of *Melissa Officinalis*, or parts thereof;
- the second composition comprises a unit dose of 100-1000 mg of *Eleutherococcus senticosus*, or parts thereof;
- 25                   - the third composition comprises a unit dose of 100-1000 mg of *Avena sativa*, or parts thereof;
- the fourth composition comprises a unit dose of 100-1000 mg *Ballota Nigra*, or parts thereof;
- the fifth composition comprises a unit dose of
- 30 100-1000 mg of the roots of *Glycyrrhiza glabra/gan cao*, or parts thereof;

- the sixth composition comprises a unit dose of 100-1000 mg of the roots of *Unicaria Tomentosa*, or parts thereof.

- 5 A second aspect of the present invention relates to a kit comprising:
- a first composition comprising leaves of *Melissa Officinalis*, or parts thereof;
  - a second composition comprising *Eleutherococcus*
  - 10 *senticosus*, or parts thereof;
  - a third composition comprising *Avena sativa*, or parts thereof;
  - a fourth composition comprising roots of *Piper*
  - methysticum, or parts thereof;
  - 15 - a fifth composition comprising roots of *Glycyrrhiza glabra/gan cao*, or parts thereof;
  - a sixth composition comprising roots of *Unicaria Tomentosa*, or parts thereof.

It is believed that one of the pharmaceutically active

20 compounds in the leaves of *Melissa Officinalis* is rose mary acid. It is further believed that the pharmaceutically active compounds of *Eleutherococcus senticosus* are present in the polyphenol-fraction. Moreover, one of the most important pharmaceutically active compounds in the roots of *Piper*

25 *methysticum* is most likely resine. Further, it is believed that the pharmaceutically active compounds of the roots of *Glycyrrhiza glabra/gan cao* are present in the saponin-fraction and that the pharmaceutically active compounds of the roots *Unicaria Tomentosa* are present in the alkaloid-

30 fraction.

The above mentioned kit is especially suited for the treatment of horses, however other mammals may also be treated with it. It is believed that administering the



compositions of the kit lifts the system-reticulo-endothelial blockade and restores the biofeedback. This leads to an improvement of the overall physical condition of the horse.

Due to the improvement of its physical condition, the  
5 homotoxins that cause the itching are broken down. This prevents the homo-toxins from accumulating in the connective tissue of the tale and mane region, resulting in less or no itching.

In a preferred embodiment of the kit of the present  
10 invention;

- the first composition comprises a unit dose of 100-1000 mg leaves of *Melissa Officinalis*, or parts thereof;
- the second composition comprises a unit dose of 100-1000 mg of *Eleutherococcus senticosus*, or parts thereof;
- 15 - the third composition comprises a unit dose of 100-1000 mg of *Avena sativa*, or parts thereof;
- the fourth composition comprises a unit dose of 100-1000 mg roots of *Piper methysticum*, or parts thereof;
- the fifth composition comprises a unit dose of 20 100-1000 mg roots of *Glycyrrhiza glabra/gan cao*, or parts thereof.
- the sixth composition comprises a unit dose of 100-1000 mg roots of *Unicaria Tomentosa*, or parts thereof.

25 In a preferred embodiment of the above mentioned kits, a composition comprises a pharmaceutically acceptable carrier. Moreover, it is preferred if a composition is in the form of a capsule or tablet, although a liquid or sachet may also be used.

30 A third aspect of the present invention relates to a kit as described above for use in the treatment of disorders in mammals, like humans, horses, cows, pigs and pets.



6

A fourth aspect of the present invention relates to a kit as described above for use in the treatment of lupus, multiple sclerosis or rheumatoid arthritis in humans or tale and mane eczema in horses.

- 5 A last aspect of the present invention relates to the use of a kit as described above as a medicament.

The invention will be described by the following examples. These examples are given for illustration purposes and are  
10 not intended to limit the scope of the invention.

# EXAMPLES

## Example 1

A Spanish female patient suffering from lupus was treated  
5 with the compositions of the kit of the present invention.  
Before treatment the patient had a poor working liver and was  
very sensitive to light. Exposure to light caused several  
inflammatory places on the skin. During 5 months the patient  
was treated with the compositions of the kit of the  
10 invention. She was administered:  
- three times a day two capsules containing 210 mg of leaves  
of Melissa Officinalis;  
- three times a day two capsules containing 250 mg of  
Eleutherococcus senticosus;  
15 - three times a day two capsules containing 250 mg of Avena  
sativa.  
- three times a day one capsule containing 150 mg of an  
extract of Ballota nigra;  
- three times a day two capsules containing 250 mg parts of  
20 the roots of Glycyrrhiza glabra/gan cao; and  
- three times a day one capsule containing 350 mg parts of  
roots of Unicaria Tomentosa.  
After 6 months the patient was exposed to day-light and no  
inflammation of the skin took place. Further, MRI-pictures  
25 were taken from the liver and they showed that the dark  
spots, indicating a poorly working liver, had disappeared.

## Example 2

A group of 102 horses (98 Fjords, 2 Icelanders and 2 Half  
30 lings) suffering from tale and mane eczema were treated with  
the compositions of the kit of the present invention. Before  
treatment the horses had several infections in the tale and

mane region. During a period varying from 1 to 6 months the horses were administered:

- three times a day two capsules containing 210 mg of leaves of *Melissa Officinalis*;
- 5 - three times a day two capsules containing 250 mg of *Eleutherococcus senticosus*;
- three times a day two capsules containing 250 mg of *Avena sativa*;
- three times a day two capsules containing 300 mg parts of
- 10 the roots of *Piper methysticum*;
- three times a day two capsules containing 250 mg parts of the roots of *Glycyrrhiza glabra*/gan cao;
- three times a day one capsule containing 350 mg parts of the roots of *Unicaria Tomentosa*.
- 15 Within a period of six months the conditions of all the horses were evaluated. Seventy nine horses did no longer suffer from tale and mane eczema. Twelve horses showed improvement, although the tale and mane eczema was not cured completely. Eleven horses showed no improvement. It is
- 20 believed that the disease has affect these eleven horses beyond a biological border, making treatment fruitless.

CLAIMS

1. Kit comprising:

- a first composition comprising leaves of  
5 *Melissa Officinalis*, or parts thereof;
- a second composition comprising *Eleutherococcus*  
*senticosus*, or parts thereof;
- a third composition comprising *Avena sativa*, or  
parts thereof;
- 10 - a fourth composition comprising *Ballota Nigra*,  
or parts thereof;
- a fifth composition comprising roots of  
*Glycyrrhiza glabra/gan cao*, or parts thereof; and
- a sixth composition comprising roots of  
15 *Unicaria Tomentosa*, or parts thereof.

2. Kit according to claim 1, wherein

- the first composition comprises a unit dose of  
100-1000 mg of leaves of *Melissa Officinalis*, or parts  
thereof;
- 20 - the second composition comprises a unit dose of  
100-1000 mg of *Eleutherococcus senticosus*, or parts thereof;
- the third composition comprises a unit dose of  
100-1000 mg of *Avena sativa*, or parts thereof;
- the fourth composition comprises a unit dose of  
25 100-1000 mg *Ballota Nigra*, or parts thereof;
- the fifth composition comprises a unit dose of  
100-1000 mg of the roots of *Glycyrrhiza glabra/gan cao*, or  
parts thereof;
- the sixth composition comprises a unit dose of  
30 100-1000 mg of the roots of *Unicaria Tomentosa*, or parts  
thereof.

3. Kit comprising:

- a first composition comprising leaves of  
Melissa Officinalis, or parts thereof;

- a second composition comprising Eleutherococcus  
senticosus, or parts thereof;

5 - a third composition comprising Avena sativa, or  
parts thereof;

- a fourth composition comprising roots of Piper  
methysticum, or parts thereof;

- a fifth composition comprising roots of  
10 Glycyrrhiza glabra/gan cao, or parts thereof;

- a sixth composition comprising roots of  
Unicaria Tomentosa, or parts thereof.

4. Kit according to claim 3, wherein

- the first composition comprises a unit dose of  
15 100-1000 mg leaves of Melissa Officinalis, or parts thereof;

- the second composition comprises a unit dose of  
100-1000 mg of Eleutherococcus senticosus, or parts thereof;

- the third composition comprises a unit dose of  
100-1000 mg of Avena sativa, or parts thereof;

20 - the fourth composition comprises a unit dose of  
100-1000 mg roots of Piper methysticum, or parts thereof;

- the fifth composition comprises a unit dose of  
100-1000 mg roots of Glycyrrhiza glabra/gan cao, or parts  
thereof.

25 - the sixth composition comprises a unit dose of  
100-1000 mg roots of Unicaria Tomentosa, or parts thereof.

5. Kit according to any of the claims 1-4, wherein a  
composition comprises a pharmaceutically acceptable carrier.

6. Kit according to claim 1-5 wherein a composition  
30 is in the form of a capsule or tablet.

7. Kit according to any of the claims 1-6 for use in  
the treatment of disorders in mammals, like humans, horses,  
cows, pigs and pets.

11

8. Kit according to any of the claims 1-6 for use in the treatment of lupus, multiple sclerosis or rheumatoid arthritis in humans or tale and mane eczema in horses.

9. Use of a kit according to claim 1-6 as a  
5 medicament.

ABSTRACT

The invention relates to a kit comprising:

- 5                   - a first composition comprising leaves of  
Melissa Officinalis, or parts thereof;
- a second composition comprising Eleutherococcus  
senticosus, or parts thereof;
- a third composition comprising Avena sativa, or  
10 parts thereof;
- a fourth composition comprising Ballota Nigra,  
or parts thereof;
- a fifth composition comprising the roots of  
Glycyrrhiza glabra/gan cao, or parts thereof; and
- 15                  - a sixth composition comprising roots of  
Unicaria Tomentosa, or parts thereof. To the kit for use in  
the treatment of disorders in mammals, like humans, horses,  
cows, pigs and pets. To the kit for use in the treatment of  
lupus, multiple sclerosis or rheumatoid arthritis in humans  
20 or tale and mane eczema in horses, and to its use as a  
medicament.